Browsing by Author "Ali, H.S."

Now showing 1 - 2 of 2

Electroanalytical Determination of Salbutamol in Pharmaceutical Formulations Using Cathodically Pretreated Boron-Doped Diamond Electrode
(Marmara University, 2018) Talay Pınar, P.; Ali, H.S.; Abdullah, A.A.; Yardim, Y.; Şentürk, Z.
This paper examined for the first time the possibilities of the usage of the cathodically pretreated boron-doped diamond (CPT-BDD) electrode for the redox behavior of salbutamol (SAL) using cyclic and adsorptive stripping voltammetry. The cyclic voltammograms showed an irreversible and adsorption-controlled oxidation peak at about +1.0 V in the Britton-Robinson (BR) buffer (pH 9.0) solution. Under the optimized experimental condition, using square-wave adsorptive stripping mode, the compound yielded a well-defined voltammetric response in BR buffer, pH 9.0 at +0.95 V (vs. Ag/AgCl) (after 30 s accumulation at an open circuit condition). A linear calibration graph was obtained in the concentration range of 4.15 to 83 μg mL-1 (1.73x10-5-3.47x10-4 M). A detection limit of 1.21 μg mL-1 (5.06x10-6 M) was observed. The suggested method was also applied to the determination of SAL in the drug formulations. © 2018 Elsevier B.V., All rights reserved.
The Rationale for Current Pharmacotherapy of Covid-19
(Yuzuncu Yil Universitesi Tip Fakultesi, 2020) Yunusoğlu, O.; Ali, H.S.
Severe acute respiratory syndrome (SARS-CoV), Middle East respiratory syndrome (MERS) and SARS-CoV-2 are related to the coronaviridae family. The worldwide pandemic of the new coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) broke out in Wuhan province of China, in December 2019, and spread rapidly throughout the world. More than 6 million cases and 370,000 deaths had been reported by 31 May 2020 in more than 200 countries. No data are available from any clinical trials supporting a proposed prophylactic therapy. More than 300 active clinical trials are currently underway. Many drugs have been studied against COVID-19, but there is no actual evidence from any randomized clinical trials with a potential therapy that can improve outcomes of a patient diagnosed with COVID-19. In some cases, many of the investigated drugs cause side effects, e.g. chloroquine, ribavirin. Besides its beneficial effects such as reducing disease progression and decreasing symptom duration, chloroquine can cause cardiac side effects. Ribavirin, on the other hand, is recognized as a teratogen and considered unsafe in pregnancy. No special effective antiviral therapy against COVID-19 is currently available. Although the course of the disease is mild and moderate in the majority of the COVID-19 patients, more than 5%-7% of the patients' life being under severely susceptible threats requires more effective medicinal products, urgently. © 2020, Yuzuncu Yil Universitesi Tip Fakultesi. All rights reserved.